Novo Nordisk A/S (NVO)
- Previous Close
143.63 - Open
141.91 - Bid 141.61 x 1000
- Ask 141.73 x 1200
- Day's Range
141.02 - 142.03 - 52 Week Range
75.56 - 143.94 - Volume
2,555,087 - Avg. Volume
3,899,825 - Market Cap (intraday)
630.814B - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
48.83 - EPS (TTM)
2.90 - Earnings Date Aug 7, 2024
- Forward Dividend & Yield 1.37 (0.95%)
- Ex-Dividend Date Mar 22, 2024
- 1y Target Est
149.84
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
www.novonordisk.comRecent News: NVO
Related Videos: NVO
Performance Overview: NVO
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVO
Valuation Measures
Market Cap
636.08B
Enterprise Value
638.63B
Trailing P/E
49.41
Forward P/E
42.37
PEG Ratio (5yr expected)
2.52
Price/Sales (ttm)
18.06
Price/Book (mrq)
44.31
Enterprise Value/Revenue
18.10
Enterprise Value/EBITDA
35.66
Financial Highlights
Profitability and Income Statement
Profit Margin
36.55%
Return on Assets (ttm)
25.24%
Return on Equity (ttm)
99.87%
Revenue (ttm)
244.24B
Net Income Avi to Common (ttm)
89.28B
Diluted EPS (ttm)
2.90
Balance Sheet and Cash Flow
Total Cash (mrq)
9.3B
Total Debt/Equity (mrq)
27.22%
Levered Free Cash Flow (ttm)
40.24B
Research Analysis: NVO
Company Insights: NVO
NVO does not have Company Insights
Research Reports: NVO
Novo Nordisk's Cardiometabolic Innovation Supports a Wide Moat
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice TargetRaising target to $160
Novo Nordisk is a pharmaceutical company based in Denmark. Its key divisions include Diabetes Care, Obesity Care, and Rare Diseases. Key products include Ozempic, Victoza, and insulin for diabetes; Wegovy and Saxenda for obesity; and treatments for rare blood and endocrine disorders. The company has approximately 66,015 employees.
RatingPrice TargetGlobal GDP Growth Forecasts Stable
The global economy is expected to grow at a consistent, but below-trend, rate for the next several quarters, according to the latest World Economic Outlook from the International Monetary Fund. By the numbers, the world economy is expected to expand 3.2% in 2024 and in 2025. Though solid, these rates are below the long-term historical global growth rate of 3.8%, due to the impact of inflation and higher interest rates. For industrialized economies (the U.S., Europe, Japan, etc.), growth is forecast at a low 1.7% in 2024, followed by 1.8% in 2025. Among the regions, the U.S. economy is expected to grow the fastest this year, at a 2.7% rate, while Japan's forecast is for 0.9%, and Europe is estimated at 0.8%. For emerging economies (China, India, Russia, Brazil, Saudi Arabia, etc.), growth forecasts call for 4.2% in 2024 and in 2025. The clear leaders are expected to be India and China, with average growth for the two years of 6.6% and 4.4%, respectively. These growth nations have different drivers: population growth in India and productivity growth in China. We factor these global growth forecasts into our asset-allocation models -- and based in part on the slow global growth rates, we continue to recommend that investors over-weight portfolios toward U.S.-based securities. Global stocks generally represent value, but the risks to growth are high.
Monday Tee Up: Fed Week
Monday Tee Up: Fed Week